Adding Docetaxel to FOLFOX/CAPOX in Gastric and Gastroesophageal Adenocarcinomas Does Not Improve Survival
In this MEDtalk from ASCO GI 2024, Dr. Anant Ramaswamy elaborates on the DOC-GC study. The study aimed to determine whether adding docetaxel to standard chemotherapy regimens (FOLFOX or CAPOX) improves survival in patients with advanced gastric and gastroesophageal adenocarcinomas, as well as to assess the usefulness of continuing chemotherapy beyond six months in this group of patients.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in